Publications Related to DecisionDx-UM

Aaberg, et al. (2014). Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clinical Opthalmology, 8, 2449-60.

Aaberg (2012). Practical approaches to needle biopsy and genetic diagnosis for ocular melanoma. Retina 2012: The Winds of Change. Lecture conducted from The American Academy of Ophthalmology, Chicago, IL.

Chappell, et al. (2012). Uveal Melanoma: molecular pattern, clinical features, and radiation response. American Journal of Ophthalmology, 227-32.

Correa & Augsburger. (2016). Independent prognostic significance of gene expression profile class and largest basal diameter of posterior uveal melanomas. American Journal of Ophthalmology, 162, 20-27 e1.

Correa & Augsburger. (2014). Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. Graefeā€™s Archive for Clinical and Experimental Ophthalmology, 252(1), 131-5.

Demirci, et al. (2015). Gene expression profiling test of uveal melanoma: prognostic validation, in American Society of Ophthalmic Plastic & Reconstructive Surgery Fall Scientific Symposium: Las Vegas, NV.

Field & Harbour. (2014). Recent developments in prognostic and predictive testing in uveal melanoma. Current Opinion in Ophthalmology, 25(3), 234-9.

Gill & Char. (2012). Uveal melanoma prognostication: from lesion size and cell type to molecular class. Canadian Journal of Ophthalmology, 47, 246-253.

Harbour (2011). Molecular research in uveal melanoma: ushering in a new standard of care. Retina Times, 29, 36-7.

Harbour & Chen. (2013). The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLOS Currents Evidence on Genomic Tests. 2013 Apr 9 [last modified: 2013 Apr 9]. Edition 1.

Harbour (2010). Genomic Research in Uveal Melanoma. Retina Today, 67-69.

Onken, et al. (2012). Collaborative Ocular Oncology Group Report Number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophth, epub. The Collaborative Ocular Melanoma Study: An Overview

Onken, et al. (2010). An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. Journal of Molecular Diagnostics, 12(4), 461-8.

Onken, et al. (2006). Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. Journal of Molecular Diagnostics, 8, 567-73.

Onken, et al. (2004). Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Research, 64, 7205-9.

Plasseraud, et al. (2016). Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. Journal of Oncology, 2016. doi:10.1155/2016/5325762.

Walter, et al. (2016). Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmology, 134(7), 734-40.

Worley, et al. (2007). Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clinical Cancer Research, 13(5), 1466-71.

 

Publications Related to DecisionDx-PRAME

Field, et al. (2016). PRAME as an independent biomarker for metastasis in uveal melanoma. Clinical Cancer Research, 22, 1234-42.

Field, et al. (2016). Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget, 7, 59209-19.

 

Publications Related to DecisionDx-Melanoma

Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.

Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010;28:2452-9.

Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin 2016;32:1599-1604. doi:10.1080/03007995.2016.1192997

Coit DG, Thompson JA, Algazi A, et al. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016;14:450-73.

Ferris LK, Farberg AS, Middlebrook B, et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol 2017;76;818-25.e3. doi: 10.1016/j.jaad.2016.11.051

Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 2015;21:175-83.

Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients with sentinel lymph node biopsy. J Am Acad Dermatol 2015;72:780-5.e3

Greenhaw BN, Brodland DG, Zitelli JA. Estimation of prognosis in invasive melanoma using a gene expression profile test. Presented at: 48th Annual Meeting of the American College of Mohs Surgery: April 29, 2016: Orlando FL.

Hsueh EC, Schwartz TL, Lizalek JM, et al. Prospective validation of gene expression profiling in primary cutaneous melanoma. J Clin Oncol 2016;34 (suppl; abstr 9565).

Melanoma of the Skin (2010). In S.B. Edge (Ed.). American Joint Committee on Cancer (pp 325-344). New York, NY: Springer.

Morton, DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med, 2014;370(7):599-609.

SEER Stat Fact Sheets: Melanoma of the Skin. Based on SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/statfacts/html/melan.html. Accessed April 26, 2017.

Zager JS, Messina J, Sondak VK, et al. Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients. J Clin Oncol 2016;34 (suppl; abstr 9581).

 

ASCO 2017 posters

Hsueh EC, DeBloom JR, Lee J, et al. Interim analysis of survival outcomes in a prospective multicenter cohort evaluating a prognostic 31-gene expression profile (GEP) test for melanoma. Poster presented at ASCO 2017 (abstract #9573).

Fleming MD, Middlebrook B, Covington KR, et al. Performance of a prognostic 31-gene expression profile test in Stage III cutaneous melanoma subjects. Poster presented at ASCO 2017 (abstract #9578).

Vetto JT, Leachman S, Middlebrook B, et al. Performance of a 31-gene expression profile (GEP) test for metastatic risk prediction in cutaneous melanomas (CM) of the head & neck. Poster presented at ASCO 2017 (abstract #9576).